176 related articles for article (PubMed ID: 16411067)
1. PRL secreting adenomas in male patients.
Ciccarelli A; Guerra E; De Rosa M; Milone F; Zarrilli S; Lombardi G; Colao A
Pituitary; 2005; 8(1):39-42. PubMed ID: 16411067
[TBL] [Abstract][Full Text] [Related]
2. Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma.
Lombardi M; Lupi I; Cosottini M; Rossi G; Manetti L; Raffaelli V; Sardella C; Martino E; Bogazzi F
Horm Metab Res; 2014 Dec; 46(13):939-42. PubMed ID: 25230324
[TBL] [Abstract][Full Text] [Related]
3. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
4. Giant prolactinomas in men: efficacy of cabergoline treatment.
Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
[TBL] [Abstract][Full Text] [Related]
5. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
[TBL] [Abstract][Full Text] [Related]
6. The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males.
De Rosa M; Ciccarelli A; Zarrilli S; Guerra E; Gaccione M; Di Sarno A; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2006 Mar; 64(3):307-13. PubMed ID: 16487441
[TBL] [Abstract][Full Text] [Related]
7. PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance.
de Castro Moreira AR; Trarbach E; Bueno CBF; Monteiro ALS; Grande IPP; Padula M; Maciel GAR; Glezer A
J Clin Endocrinol Metab; 2023 Jun; 108(7):e450-e457. PubMed ID: 36638053
[TBL] [Abstract][Full Text] [Related]
8. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.
De Rosa M; Colao A; Di Sarno A; Ferone D; Landi ML; Zarrilli S; Paesano L; Merola B; Lombardi G
Eur J Endocrinol; 1998 Mar; 138(3):286-93. PubMed ID: 9539303
[TBL] [Abstract][Full Text] [Related]
9. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline.
Biller BM; Molitch ME; Vance ML; Cannistraro KB; Davis KR; Simons JA; Schoenfelder JR; Klibanski A
J Clin Endocrinol Metab; 1996 Jun; 81(6):2338-43. PubMed ID: 8964874
[TBL] [Abstract][Full Text] [Related]
10. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
[TBL] [Abstract][Full Text] [Related]
11. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
[TBL] [Abstract][Full Text] [Related]
12. [Current diagnosis and treatment of hyperprolactinemia].
Melgar V; Espinosa E; Sosa E; Rangel MJ; Cuenca D; Ramírez C; Mercado M
Rev Med Inst Mex Seguro Soc; 2016; 54(1):111-21. PubMed ID: 26820213
[TBL] [Abstract][Full Text] [Related]
13. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
14. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
[TBL] [Abstract][Full Text] [Related]
15. Resistant prolactinomas: a case series of 26 patients.
Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
[TBL] [Abstract][Full Text] [Related]
16. Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline.
Cannavò S; Bartolone L; Blandino A; Spinella S; Galatioto S; Trimarchi F
J Endocrinol Invest; 1999 Apr; 22(4):306-9. PubMed ID: 10342366
[TBL] [Abstract][Full Text] [Related]
17. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
Gillam MP; Middler S; Freed DJ; Molitch ME
J Clin Endocrinol Metab; 2002 Oct; 87(10):4447-51. PubMed ID: 12364416
[TBL] [Abstract][Full Text] [Related]
18. Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients.
Ceccato F; Lizzul L; Voltan G; Barbot M; Scaroni C
Pituitary; 2021 Dec; 24(6):914-921. PubMed ID: 34173929
[TBL] [Abstract][Full Text] [Related]
19. Prolactinomas and pregnancy.
Molitch ME
Clin Endocrinol (Oxf); 2010 Aug; 73(2):147-8. PubMed ID: 20550542
[No Abstract] [Full Text] [Related]
20. Dopamine Agonists: From the 1970s to Today.
Auriemma RS; Pirchio R; De Alcubierre D; Pivonello R; Colao A
Neuroendocrinology; 2019; 109(1):34-41. PubMed ID: 30852578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
